drugset / Trial / NCT03220165

Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

NCT03220165

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is determine in healthy males how MGL-3196 is metabolized using a radio-labeled version of MGL-3196.

Timeline

Start
2017-08-06
Primary completion
2017-09-03
Completion
2017-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Resmetirom Small molecule 100 mg Oral

Indications

No indication recorded.